Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 6727
Drug: BIBF 1120

First Posted Date: 2009-12-01

Last Posted Date: 2018-07-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT01022853

Locations: 🇮🇹
1230.7.39002 Boehringer Ingelheim Investigational Site, Ancona, Italy
🇮🇹
1230.7.39001 Boehringer Ingelheim Investigational Site, Milano, Italy

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Combivent Respimat 20/100 mcg
Drug: Combivent CFC-MDI
Drug: Atrovent HFA 42 mcg + Albuterol HFA 200 mcg

First Posted Date: 2009-11-25

Last Posted Date: 2014-10-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 470

Registration Number: NCT01019694

Locations: 🇺🇸
1012.62.117 Boehringer Ingelheim Investigational Site, Livonia, Michigan, United States
🇺🇸
1012.62.126 Boehringer Ingelheim Investigational Site, Fort Collins, Colorado, United States
🇺🇸
1012.62.123 Boehringer Ingelheim Investigational Site, Waterbury, Connecticut, United States

and more 52 locations

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Phase 3

Completed

Conditions: Ovarian Neoplasms
Peritoneal Neoplasms

Interventions: Drug: BIBF 1120
Drug: Placebo
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-11-18

Last Posted Date: 2017-12-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1366

Registration Number: NCT01015118

Locations: 🇺🇸
1199.15.10019 Boehringer Ingelheim Investigational Site, Bismarck, North Dakota, United States
🇺🇸
1199.15.10024 Boehringer Ingelheim Investigational Site, Canton, Ohio, United States
🇺🇸
1199.15.10107 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States

and more 278 locations

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Olodaterol (BI 1744) low
Drug: Olodaterol (BI 1744) high
Drug: Olodaterol (BI 1744) medium
Drug: Formoterol 12 mcg
Drug: Olodaterol (BI 1744) very low
Drug: Placebo

First Posted Date: 2009-11-16

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 198

Registration Number: NCT01013753

Locations: 🇦🇹
1222.27.43004 Boehringer Ingelheim Investigational Site, Schlüsslberg, Austria
🇵🇱
1222.27.48001 Boehringer Ingelheim Investigational Site, Lodz, Poland
🇵🇱
1222.27.48004 Boehringer Ingelheim Investigational Site, Proszowice, Poland

and more 24 locations

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773 placebo
Drug: BI 10773 low dose
Drug: BI 10773 high dose

First Posted Date: 2009-11-11

Last Posted Date: 2014-09-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 494

Registration Number: NCT01011868

Locations: 🇺🇸
1245.33.01060 Boehringer Ingelheim Investigational Site, Fresno, California, United States
🇺🇸
1245.33.01008 Boehringer Ingelheim Investigational Site, Los Gatos, California, United States
🇺🇸
1245.33.01019 Boehringer Ingelheim Investigational Site, National City, California, United States

and more 96 locations

Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: linagliptin medium dose
Drug: linagliptin low dose
Drug: placebo

First Posted Date: 2009-11-11

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 491

Registration Number: NCT01012037

Locations: 🇨🇦
1218.62.11007 Boehringer Ingelheim Investigational Site, Burnaby, British Columbia, Canada
🇧🇪
1218.62.32009 Boehringer Ingelheim Investigational Site, Kumtich, Belgium
🇳🇱
1218.62.31001 Boehringer Ingelheim Investigational Site, Oude Pekela, Netherlands

and more 81 locations

Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season

Phase 2

Completed

Conditions: Rhinitis, Allergic, Seasonal
Asthma

Interventions: Drug: BI 67100 ED 25 mg
Drug: montelukast placebo tablet
Drug: BI 671800 ED 100 mg
Drug: BI 671800 ED placebo
Drug: 671800 ED placebo
Drug: Fluticasonepropionate nasal spray 200 mcg
Drug: montelukast 10 mg tablet
Drug: fluticasone propionate nasal spray placebo
Drug: fluticasone propionate placebo nasal spray

First Posted Date: 2009-11-04

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 146

Registration Number: NCT01007721

Locations: 🇩🇪
1268.41.49001 Boehringer Ingelheim Investigational Site, Hannover, Germany

Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European Region

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2009-11-01

Last Posted Date: 2014-04-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4852

Registration Number: NCT01006135

Locations: 🇵🇱
Boehringer Ingelheim Investigational Site 229, Nowy Sacz, Poland
🇵🇱
Boehringer Ingelheim Investigational Site 234, Olawa, Poland
🇵🇱
Boehringer Ingelheim Investigational Site 238, Olesnica, Poland

and more 861 locations

Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: BIBF 1120
Drug: Sorafenib

First Posted Date: 2009-10-29

Last Posted Date: 2017-10-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 125

Registration Number: NCT01004003

Locations: 🇫🇷
1199.37.33002 Boehringer Ingelheim Investigational Site, Paris, France
🇩🇪
1199.37.49003 Boehringer Ingelheim Investigational Site, München, Germany
🇵🇱
1199.37.48003 Boehringer Ingelheim Investigational Site, Warsaw, Poland

and more 25 locations

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: afatinib (BIBW 2992)

First Posted Date: 2009-10-29

Last Posted Date: 2013-12-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 43

Registration Number: NCT01003899

Locations: 🇰🇷
1200.72.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
🇰🇷
1200.72.8203 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
🇰🇷
1200.72.8202 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy